Tremfya is the first and only interleukin-23 inhibitor offering both subcutaneous and intravenous induction options for Crohn ...

Crohn's disease belongs to a group of conditions known as inflammatory bowel diseases (IBD). This chronic condition causes ...

Patients with moderate to severe Crohn’s disease who did not achieve clinical response to IV induction with Skyrizi ...

Guselkumab is the first and only interleukin-23 inhibitor that offers both subcutaneous and intravenous induction options for ...

A plant-based diet made up of mainly nutrient-dense plant foods, or an equally healthy omnivorous diet may help reduce the ...

For the first time, researchers have found strong evidence that Epstein-Barr virus (EBV), which is best known for causing mononucleosis (or “mono”), may play a role in the development of Crohn’s ...

June 10, 2024 — Scientists have grown 'mini-guts' in the lab to help understand Crohn's disease, showing that 'switches' that modify DNA in gut cells play an important role in the disease ...

In patients with Crohn's disease and intermediate to high preoperative corticosteroid use, primary ileocaecal resection leads ...

The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adults with moderately to severely active Crohn disease (CD).

New study shows that dysfunction of protective immune cells in GI tract may contribute to onset of inflammation in Crohn's disease.

The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with ...

Crohn's disease is a type of inflammatory bowel disease (IBD) that causes swelling and irritation of the tissues, called ...